SERCA2a SUMOylation Modulation for Heart Failure Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cardiovascular diseases, particularly heart failure, are inadequate in effectively addressing the modulation of SERCA2a, a critical ATPase responsible for Ca2+ re-uptake in cardiac muscle cells, which is down-regulated in failing hearts, leading to impaired cardiac function.
Innovation Solution
The use of SUMO1 overexpression to enhance the enzymatic activity and stability of SERCA2a through post-translational modification, specifically targeting the SUMOylation of SERCA2a to restore impaired cardiac function in failing hearts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If SERCA2a levels are restored by gene transfer, then systolic and diastolic dysfunction is improved, but the expression level and activity of SERCA2a remain down-regulated in failing hearts
Solution Approach 1:
The patent applies post-translational modification (SUMOylation) to change the functional parameters of SERCA2a protein. By modifying the protein at the post-translational level rather than increasing gene expression, the patent achieves enhanced enzymatic activity and stability of SERCA2a, thereby improving cardiac function without needing to increase the quantity of SERCA2a protein expression
Solution Approach 2:
The patent introduces SUMO1 as an intermediary molecule that modifies SERCA2a through SUMOylation. This intermediary modification process enhances SERCA2a function by improving its enzymatic activity and stability, providing a novel mechanism to address SERCA2a down-regulation in heart failure without directly increasing SERCA2a expression levels
2Productivity
If SERCA2a activity is increased to improve Ca2+ re-uptake, then contractile dysfunction is ameliorated, but SERCA2a stability is reduced in failing hearts
Solution Approach 1:
The patent uses SUMOylation to change the stability parameter of SERCA2a protein. This post-translational modification enhances SERCA2a stability by preventing proteasomal degradation, thereby maintaining higher levels of functional SERCA2a protein in failing hearts without altering the primary protein structure or requiring increased expression
Solution Approach 2:
SUMO1 acts as an intermediary that binds to SERCA2a through SUMOylation, providing protective effects that enhance protein stability. This intermediary modification prevents SERCA2a degradation while maintaining or enhancing its Ca2+ pump activity, resolving the contradiction between activity and stability
Data Source
AI summary
Methods for treating cardiovascular disease, and in particular heart failure, are provided comprising administering a therapeutically effective amount of a modulator of SERCA2a post-translation modification such as SUMOylation or acetylation. Also provided are methods of treating cardiovascular disease by inhibiting SERCA2a degradation. Further provided are methods of diagnosing a propensity to develop heart failure comprising determining if a SERCA2a mutant is present or determining the level of expression of SUMO1 in cardiomyocytes. The disclosure also provides methods of screening for therapeutics that modulate the post-translational modification of SERCA2a, such as by modulating post-translational SUMOylation and/or acetylation.